Title : MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.

Pub. Date : 2017 Feb 28

PMID : 27588400






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Here we show that the MEK inhibitors Trametinib, Selumetinib and MEK162 severely impair primary RAS-mutant MLL-rearranged infant ALL cells in vitro. trametinib lysine methyltransferase 2A Homo sapiens